BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36197314)

  • 1. Subclones of bone marrow CD34
    Jia R; Ji M; Li G; Xia Y; Guo S; Li P; Sun Y; Lu F; Zhang J; Zang S; Yan S; Ye J; Xue F; Ma D; Sun T; Ji C
    Cancer; 2022 Nov; 128(22):3929-3942. PubMed ID: 36197314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy].
    Zhang CP; Wei H; Wang HJ; Huai L; He K; Chen YR; Lin D; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1268-72. PubMed ID: 22040986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia-induced functional inhibition of healthy CD34+ hematopoietic stem and progenitor cells.
    Jäger P; Geyh S; Twarock S; Cadeddu RP; Rabes P; Koch A; Maus U; Hesper T; Zilkens C; Rautenberg C; Bormann F; Köhrer K; Petzsch P; Wieczorek D; Betz B; Surowy H; Hildebrandt B; Germing U; Kobbe G; Haas R; Schroeder T
    Stem Cells; 2021 Sep; 39(9):1270-1284. PubMed ID: 34013984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
    Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
    Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia.
    Chávez-González A; Dorantes-Acosta E; Moreno-Lorenzana D; Alvarado-Moreno A; Arriaga-Pizano L; Mayani H
    Arch Med Res; 2014 May; 45(4):343-50. PubMed ID: 24751333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Relationship between Body Mass Index and Adult Acute Myeloid Leukemia].
    Wang YN; Wei T; Xi YM; Yang MY; Niu L; Wang XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):677-684. PubMed ID: 34105456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015.
    Wang CY; Huang HH; Chen HM; Hsiao FY; Ko BS
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e649-e657. PubMed ID: 33931380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome.
    Jiang L; Li XP; Dai YT; Chen B; Weng XQ; Xiong SM; Zhang M; Huang JY; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20117-20126. PubMed ID: 32747558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of AC133 vs. CD34 in acute childhood leukemias].
    Ebener U; Brinkmann A; Zotova V; Niegemann E; Wehner S
    Klin Padiatr; 2000; 212(3):90-8. PubMed ID: 10916777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?
    Ravandi F
    Best Pract Res Clin Haematol; 2014; 27(3-4):241-6. PubMed ID: 25455273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD45
    Heo SK; Noh EK; Ju LJ; Sung JY; Jeong YK; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Apr; 20(1):285. PubMed ID: 32252668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.
    Chen X; Tang Y; Chen J; Chen R; Gu L; Xue H; Pan C; Tang J; Shen S
    Front Med; 2019 Jun; 13(3):378-387. PubMed ID: 30635781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
    Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
    J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry.
    Kanter-Lewensohn L; Hellström-Lindberg E; Kock Y; Elmhorn-Rosenborg A; Ost A
    Eur J Haematol; 1996 Mar; 56(3):124-9. PubMed ID: 8598230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.